Nutrinia’s Short Bowel Study

The NTRA-9620 drug product is intended to enhance post-resection bowel adaptation and improve patient outcomes. This includes reducing reliance on parenteral nutrition support and increasing enteral nutrition intake. Nutrinia plans to begin a pivotal clinical trial in this indication.  The new treatment is aimed at helping thousands of patients worldwide, reducing their dependence on parenteral nutrition, which puts them at a higher risk for liver disease, infections, and other complications. 

Share This Post...

About The Author: Graham's Foundation

Comments are closed, but trackbacks and pingbacks are open.